39 related articles for article (PubMed ID: 30767873)
1. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.
Moinzadeh P; Fonseca C; Hellmich M; Shah AA; Chighizola C; Denton CP; Ong VH
Arthritis Res Ther; 2014 Feb; 16(1):R53. PubMed ID: 24524733
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of patients with systemic sclerosis positive for anti-SS-A antibody: a cohort study of 156 patients.
Watanabe T; Ototake Y; Akita A; Suzuki M; Kanaoka M; Tamura J; Saigusa Y; Yamaguchi Y
Arthritis Res Ther; 2024 May; 26(1):93. PubMed ID: 38702799
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of anti-IFI16 autoantibodies in pulmonary arterial hypertension and mortality in patients with systemic sclerosis.
Perurena-Prieto J; Callejas-Moraga EL; Sanz-Martínez MT; Colobran R; Guillén-Del-Castillo A; Simeón-Aznar CP
Med Clin (Barc); 2024 Apr; 162(8):370-377. PubMed ID: 38302398
[TBL] [Abstract][Full Text] [Related]
4. Protective Effect Against Cancer of Antibodies to the Large Subunits of Both RNA Polymerases I and III in Scleroderma.
Shah AA; Laiho M; Rosen A; Casciola-Rosen L
Arthritis Rheumatol; 2019 Sep; 71(9):1571-1579. PubMed ID: 30888702
[TBL] [Abstract][Full Text] [Related]
5. Proximal weakness and creatine kinase elevation in systemic sclerosis: Clinical correlates, prognosis and functional implications.
Fairley JL; Hansen D; Day J; Proudman S; Sahhar J; Ngian GS; Walker J; Host LV; Morrisroe K; Stevens W; Ross L; Nikpour M
Semin Arthritis Rheum; 2024 Apr; 65():152363. PubMed ID: 38316069
[TBL] [Abstract][Full Text] [Related]
6. Analysis of anti-RNA polymerase III antibodies in Chinese Han systemic sclerosis patients.
Liu C; Hou Y; Xu D; Li L; Zhang Y; Cheng L; Yan S; Zhang F; Li Y
Clin Rheumatol; 2020 Apr; 39(4):1191-1197. PubMed ID: 31858335
[TBL] [Abstract][Full Text] [Related]
7. Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis.
Lazzaroni MG; Campochiaro C; Bertoldo E; De Luca G; Caimmi C; Tincani A; Franceschini F; Airò P
Clin Exp Rheumatol; 2021; 39 Suppl 131(4):25-28. PubMed ID: 33337991
[TBL] [Abstract][Full Text] [Related]
8. Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival.
Watad A; McGonagle D; Bragazzi NL; Tiosano S; Comaneshter D; Shoenfeld Y; Cohen AD; Amital H
Oncoimmunology; 2019; 8(6):e1588084. PubMed ID: 31069155
[No Abstract] [Full Text] [Related]
9. The Pathogenesis of Systemic Sclerosis: The Origin of Fibrosis and Interlink with Vasculopathy and Autoimmunity.
Ko J; Noviani M; Chellamuthu VR; Albani S; Low AHL
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762589
[TBL] [Abstract][Full Text] [Related]
10. Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course.
Kim JS; Woods A; Gutierrez-Alamillo L; Laffoon M; Wigley FM; Hummers LK; Rosen A; Zeger S; Domsic RT; Casciola-Rosen L; Shah AA
Arthritis Rheumatol; 2024 Jan; 76(1):68-77. PubMed ID: 37488962
[TBL] [Abstract][Full Text] [Related]
11. Systemic Sclerosis Association with Malignancy.
Lepri G; Catalano M; Bellando-Randone S; Pillozzi S; Giommoni E; Giorgione R; Botteri C; Matucci-Cerinic M; Antonuzzo L; Guiducci S
Clin Rev Allergy Immunol; 2022 Dec; 63(3):398-416. PubMed ID: 36121543
[TBL] [Abstract][Full Text] [Related]
12. Capillaroscopy and Immunological Profile in Systemic Sclerosis.
Lambova SN; Kurteva EK; Dzhambazova SS; Vasilev GH; Kyurkchiev DS; Geneva-Popova MG
Life (Basel); 2022 Mar; 12(4):. PubMed ID: 35454989
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort.
Jaafar S; Lescoat A; Huang S; Gordon J; Hinchcliff M; Shah AA; Assassi S; Domsic R; Bernstein EJ; Steen V; Elliott S; Hant F; Castelino FV; Shanmugam VK; Correia C; Varga J; Nagaraja V; Roofeh D; Frech T; Khanna D
Arthritis Res Ther; 2021 Jun; 23(1):170. PubMed ID: 34127049
[TBL] [Abstract][Full Text] [Related]
14. Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification.
Yang C; Tang S; Zhu D; Ding Y; Qiao J
Front Med (Lausanne); 2020; 7():587773. PubMed ID: 33330547
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain.
Callejas-Moraga EL; Guillén-Del-Castillo A; Marín-Sánchez AM; Roca-Herrera M; Balada E; Tolosa-Vilella C; Fonollosa-Pla V; Simeón-Aznar CP
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):41-48. PubMed ID: 30767873
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.
Nikpour M; Hissaria P; Byron J; Sahhar J; Micallef M; Paspaliaris W; Roddy J; Nash P; Sturgess A; Proudman S; Stevens W
Arthritis Res Ther; 2011; 13(6):R211. PubMed ID: 22189167
[TBL] [Abstract][Full Text] [Related]
17. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
18. Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.
Ceribelli A; Krzyszczak ME; Li Y; Ross SJ; Chan JY; Chan EK; Burlingame RW; Webb TT; Bubb MR; Sobel ES; Reeves WH; Satoh M
Arthritis Res Ther; 2011 Jul; 13(4):R119. PubMed ID: 21781293
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis.
Sobanski V; Dauchet L; Lefèvre G; Lambert M; Morell-Dubois S; Sy T; Hachulla E; Hatron PY; Launay D; Dubucquoi S
Arthritis Rheumatol; 2014 Feb; 66(2):407-17. PubMed ID: 24504813
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
